United States, Food and Drug Administration
Resource Information
The concept United States, Food and Drug Administration represents the subject, aboutness, idea or notion of resources found in University of Missouri-St. Louis Libraries.
The Resource
United States, Food and Drug Administration
Resource Information
The concept United States, Food and Drug Administration represents the subject, aboutness, idea or notion of resources found in University of Missouri-St. Louis Libraries.
- Label
- United States, Food and Drug Administration
- Authority link
- http://id.worldcat.org/fast/00549734
- Numeration
- Food and Drug Administration
- Source
- fast
- Subordinate unit
- Food and Drug Administration
77 Items that share the Concept United States, Food and Drug Administration
Context
Context of United States, Food and Drug AdministrationSubject of
No resources found
No enriched resources found
- A risk-characterization framework for decision-making at the Food and Drug Administration
- Acceptable risks : politics, policy, and risky technologies
- Advancing regulatory science for medical countermeasure development : workshop summary
- Advancing the discipline of regulatory science for medical product development : an update on progress and a forward-looking agenda : workshop summary
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2015 : report (to accompany S. 2389)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2015 : report together with minority views (to accompany H.R. 4800)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2016 : report (to accompany S. 1800)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2016 : report (to accompany S. 1800)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2016 : report together with minority views (to accompany H.R. 3049)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2017 : report (to accompany S. 2956)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2017 : report together with dissenting and additional views (to accompany H.R. 5054)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2020 : report together with minority views (to accompany H.R. 3164)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2021 : report together with minority views (to accompany H.R. 7610)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2022 : report together with minority views (to accompany H.R. 4356)
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations for 2016 : hearings before a Subcommittee of the Committee on Appropriations, House of Representatives, One Hundred Fourteenth Congress, first session
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations for 2020 : hearings before a Subcommittee of the Committee on Appropriations, House of Representatives, One Hundred Sixteenth Congress, first session
- Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations for fiscal year 2014 : hearings before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Thirteenth Congress, first session on H.R. 2410/S. 1244, an act making appropriations for Agriculture, Rural Development, Food and Drug Administration, and related agencies programs for the fiscal year ending September 30, 2014, and for other purposes
- Animal drug user fee agreements : advancing animal health for the public : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Thirteenth Congress, first session ... February 27, 2013
- Antibiotics, FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to congressional requesters
- Assuring data quality and validity in clinical trials for regulatory decision making : workshop report : Roundtable on Research and Development of Drugs, Biologics, and Medical Devices
- Biosimilar implementation : a progress report from FDA : hearing before the Subcommittee on Primary Health and Retirement Security of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, first session ... September 17, 2015
- Building a national framework for the establishment of regulatory science for drug development : workshop summary
- Challenges for the FDA : the Future of Drug Safety : Workshop Summary
- Compassionate use and emergency use authorization for unapproved drugs : FDA policies and background
- Continuing concerns over imported pharmaceuticals : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, June 7, 2001
- Cost-contained regulatory compliance : for the pharmaceutical, biologics, and medical device industries
- Delays in the FDA's food additive petition process and GRAS affirmation process : hearings before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, June 22 and 29, 1995
- Development and approval of combination products : a regulatory perspective
- Development of FDA-regulated medical products : a translational approach
- Dietary Supplement Health and Education Act : is the FDA trying to change the intent of Congress? : hearing before the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session, March 25, 1999
- Dietary supplements : a framework for evaluating safety
- Drug compounding : background, issues and FDA oversight
- Drug compounding, FDA has taken steps to implement compounding law, but some states and stakeholders reported challenges : report to Congressional Committees
- Drug safety : most drugs withdrawn in recent years had greater health risks for women
- Drug safety, FDA has improved its foreign drug inspection program, but needs to assess the effectiveness and staffing of its foreign offices : report to the Committee on Energy and Commerce
- Drug safety: COVID-19 complicates already challenged FDA foreign inspection program : testimony before the Committee on Finance, U.S. Senate
- Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog : testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives
- Enhancing food safety : the role of the Food and Drug Administration
- FDA in the twenty-first century : the challenges of regulating drugs and new technologies
- FDA medical device reviews, evaluation is needed to assure requests for additional information follow a least burdensome approach : report to congressional requesters
- FDA medical product approvals : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, August 8, 1995
- FDA regulation of blood safety : notification, recall, and enforcement practices : hearing before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, June 5, 1997
- FDA regulation of medical devices, including the status of breast implants : joint hearing before the Subcommittee on Human Resources and Intergovernmental Relations and the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, August 1, 1995
- FDA regulation of tobacco products
- FDA regulation of tobacco products
- Fairness in Orphan Drug Exclusivity Act : report (to accompany H.R. 4712)
- Food and Drug Administration : revenue information on certain companies participating in the Medical Device User Fee Program
- Food and Drug Administration: information on Mifeprex labeling changes and ongoing monitoring efforts : report to congressional requesters
- Food and Drug enforcement standards for medical devices : joint hearing before the Subcommittee on Human Resources and Intergovernmental Relations and the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, September 14, 1995
- Food issues, policies and safety considerations, Volume 4
- Food issues, policies, and safety considerations, Volume 5
- Food labelling : the FDA's role in the selection of healthy foods
- Food safety, FDA's efforts to evaluate and respond to business concerns regarding the produce rule
- Food safety: federal efforts to manage the risk of arsenic in rice : report to the Ranking Member, Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, Committee on Appropriations, House of Representatives
- H.R. 3504: Pesticide Monitoring Improvements Act
- How accurate is the FDA's monitoring of supplements like ephedra? : hearing before the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session, May 27, 1999
- Information technology, FDA has taken steps to address challenges but needs a comprehensive strategic plan : report to congressional committees
- Medicaid Pharmaceutical Home Act of 2018 : report together with additional views (to accompany H.R. 5808) (including cost estimate of the Congressional Budget Office)
- Medical devices : protecting patients and promoting innovation : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Twelfth Congress, first session ... November 15, 2011
- Off-label drug use and FDA review of supplemental drug applications : hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 : report together with additional views (to accompany H.R. 5333) (including cost estimate of the Congressional Budget Office)
- Oversight of NIH and FDA : bioethics and the adequacy of informed consent : hearing before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, May 8, 1997
- Patient access to alternative treatments : beyond the FDA : hearings before the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, second session, February 4 and 12, 1998
- Personalized medicine and the FDA's emerging role
- Protecting the public health : examining FDA's initiatives and priorities : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Thirteenth Congress, second session ... March 13, 2014
- Public health effectiveness of the FDA 510(k) clearance process : balancing patient safety and innovation : workshop report
- Public health effectiveness of the FDA 510(k) clearance process : measuring postmarket performance and other select topics : workshop report
- Reputation and power : organizational image and pharmaceutical regulation at the FDA
- Safety of the U.S. food supply : continuing concerns over the Food and Drug Administration's food-recall process : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, second session, January 19, 2018
- Strengthening a workforce for innovative regulatory science in therapeutics development : workshop summary
- The future of drug safety : promoting and protecting the health of the public
- The need for FDA regulatory reform to protect the health and safety of Americans : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, June 9, 1995
- The risks of prescription drugs
- The trials of psychedelic therapy : LSD psychotherapy in the United States
- Unlocking the cures for America's most deadly diseases : hearing before the Subcommittee on Space, Science, and Competitiveness of the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Fourteenth Congress, first session, July 14, 2015
- When diets turn deadly : consumer safety and weight-loss supplements : hearing before the Oversight of Government Management, Restructuring, and the District of Columbia Subcommittee of the Committee on Governmental Affairs, United States Senate, One Hundred Seventh Congress, second session, July 31, 2002
- Year 2000 computing crisis: readiness of Medicare and the health care sector: : testimony before the Subcommittee on Oversight and Investigations and the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.umsl.edu/resource/u8AYUQ28YRY/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.umsl.edu/resource/u8AYUQ28YRY/">United States, Food and Drug Administration</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.umsl.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.umsl.edu/">University of Missouri-St. Louis Libraries</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Concept United States, Food and Drug Administration
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.umsl.edu/resource/u8AYUQ28YRY/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.umsl.edu/resource/u8AYUQ28YRY/">United States, Food and Drug Administration</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.umsl.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.umsl.edu/">University of Missouri-St. Louis Libraries</a></span></span></span></span></div>
